1. Identification of β-Lactams Active against
- Author
-
Ben, Gold, Jun, Zhang, Landys Lopez, Quezada, Julia, Roberts, Yan, Ling, Madeleine, Wood, Wasima, Shinwari, Laurent, Goullieux, Christine, Roubert, Laurent, Fraisse, Eric, Bacqué, Sophie, Lagrange, Bruno, Filoche-Rommé, Michal, Vieth, Philip A, Hipskind, Louis N, Jungheim, Jeffrey, Aubé, Sarah M, Scarry, Stacey L, McDonald, Kelin, Li, Andrew, Perkowski, Quyen, Nguyen, Véronique, Dartois, Matthew, Zimmerman, David B, Olsen, Katherine, Young, Shilah, Bonnett, Douglas, Joerss, Tanya, Parish, Helena I, Boshoff, Kriti, Arora, Clifton E, Barry, Laura, Guijarro, Sara, Anca, Joaquín, Rullas, Beatriz, Rodríguez-Salguero, Maria S, Martínez-Martínez, Esther, Porras-De Francisco, Monica, Cacho, David, Barros-Aguirre, Paul, Smith, Steven J, Berthel, Carl, Nathan, and Robert H, Bates
- Subjects
Mice ,Drug Industry ,Universities ,SARS-CoV-2 ,Animals ,COVID-19 ,Mycobacterium tuberculosis ,beta-Lactams - Abstract
Rising antimicrobial resistance challenges our ability to combat bacterial infections. The problem is acute for tuberculosis (TB), the leading cause of death from infection before COVID-19. Here, we developed a framework for multiple pharmaceutical companies to share proprietary information and compounds with multiple laboratories in the academic and government sectors for a broad examination of the ability of β-lactams to kill
- Published
- 2022